Improving outcomes in community-acquired pneumonia

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 3, 2016, Pages 235-242

  Bender, Michael T ^a   Niederman, Michael S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

antibiotic therapy; cardiac disease; comorbidities; pneumonia outcomes; readmission

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; HOSPITAL READMISSION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMMUNITY-ACQUIRED INFECTIONS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; PROGNOSIS; REMISSION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; PROGNOSIS; REMISSION INDUCTION;

EID: 84957831090     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000257     Document Type: Review

References (68)

1. Gray BM, Musher DM. The history of pneumococcal disease. In: Siber G, Klugman KP, Makela P, editors. Pneumococcal vaccines: the impact of conjugate vaccine. Washington DC: ASM Press; 2008. pp. 3-17.
2. Fine MJ, Auble TE, Yearly DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 33:243-250.
3. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013; 309:355-363.
4. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997; 12:423-430.
5. Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis 2013; 56:1145-1146.
6. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37:1409-1420.
7. Wiemken T, Kelley R, Ramirez J. Clinical scoring tools: which is best to predict clinical response and long-term outcomes? Infect Dis Clin North Am 2013; 27:33-48.
8. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007; 132:515-522.
9. Chen JH, Chang SS, Liu JJ, et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly, and very old subjects. Thorax 2010; 65:971-977.
10. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000; 55:219-223.
11. Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patient aged >75 years. Eur Respir J 2001; 17:200-205.
12. Wesemann T, Nullmann H, Pflug MA, et al. Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study. BMC Infect Dis 2015; 15:2.
13. Kolditz M, Ewig S, Schutte H, et al. Assessment of oxygenation and comor-bidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med 2015; 278:193-202.
14. Dwyer R, Hedlund J, Henriques-Normark B, et al. Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia. BMJ Open Resp Res 2014; 1:e000038.
15. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375-384.
16. Myint PK, Kamath AV, Vowler SL, et al. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? Age Ageing 2006; 35:286-291.
17. Subramanian DN, Musonda P, Sankaran P, et al. Performance of SOAR (systolic blood pressure, oxygenation, age and respiratory rate) scoring criteria in community-acquired pneumonia: a prospective multi-centre study. Age Ageing 2013; 42:94-97.
18. Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe community acquired pneumonia using meta-analysis and observational data. Eur Respir J 2014; 43:842-851.
19. Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013; 41:974-984.
20. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52:48-58.
21. Laserna E, Sibila O, Aguilar PR, et al. Hypocapnia and hypercapnia are predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia. Chest 2012; 142:1193-1199.
22. Prina E, Ferrer M, Ranzani OT, et al. Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. Chest 2013; 143:767-775.
23. Hraiech S, Alingrin J, Dizier S, et al. Time to intubation is associated with outcome in patients with community-acquired pneumonia. PLoS One 2013; 8:e74937.
24. Kruger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short-and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182:1426-1434.
25. Santos-Gallego CG, Badimon JJ. Cardiac complications after community-acquired pneumonia. Am J Cardiol 2015; 117:310.
26. Musher DM, Rueda AM, Kaka AS, et al. Theassociation between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45:158-165.
27. Ramirez JA, Aliberti S, Mirsaeidi M, et al. Acute mycocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47:182-187.
28. Carr GE, Yuen TC, McConville JF, et al. Hospital cardiac arrest among patients with coexisting pneumonia: a report from the American Heart Association's get with the guidelines-resuscitation program. Chest 2012; 141:1528-1536.
29. Cangemi R, Calvieri C, Falcone M, et al. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. Am J Cardiol 2015; 116:647-651.
30. Brown AO, Millett ER, Quint JK, et al. Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 2015; 191:739-745.
31. Cangemi R, Cascario M, Ross E, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014; 64:1917-1925.
32. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27-S72.
33. Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11-18.
34. Marrie TJ, Poulin-Costello M, Beecroft MD, et al. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60-65.
35. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340-346.
36. Falguera M, Carratala J, Ruiz-Gonzalez A, et al. Risk factors and outcome of community-acquired pneumonia due to gram-negative bacilli. Respirology 2009; 14:105-111.
37. Jain S, Self WH, Wunderink RG, et al. Community acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373:415-427.
38. Johnston J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort. Medicine 2008; 87:329-334.
39. Metersky ML, Waterer G, Nsa W, et al. Predictors of in-hospital vs post-discharge mortality in pneumonia. Chest 2012; 142:476-481.
40. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372:1312-1323.
41. Garin N, Genne D, Carballo S, et al. p-lactam monotherapy vs p-lactam-macrolid combination treatment in moderately severe community-acquired pneuomina: a randomized noninferiority trial. JAMA Intern Med 2014; 174:1894-1901.
42. Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and metaanalysis. Crit Care Med 2014; 42:420-432.
43. Gatarello S, Borgatta B, Sole-Violan J, et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014; 146:22-31.
44. McEvoy C, Micek ST, Reichley RM, et al. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired pneumonia but not healthcare-associated pneumonia. Surg Infect 2014; 15:283-289.
45. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-1890.
46. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311:2199-2208.
47. Wunderink RG. How is important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is the best antimicrobial therapy? Inf Dis Clin North Am 2013; 27:177-188.
48. Diep BA, Afasizheva A, Le HN, et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and survival outcomes in a rabbit model of MRSA necrotizing pneumonia. J Infect Dis 2013; 208:75-82.
49. Sicot N, Khanafer N, Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired pneumonia: results of prospective observational study. Clin Microbiol Infect 2013; 19:E142-E148.
50. Faris J, Mynatt RP, Snyder ADH, et al. Treatment of methicillin-resistant staphylococcal aureus (MRSA) pneumonia with ceftaroline fosamil in a patient with inhalational thermal injury. Infect Dis Ther 2015; 4:519-528.
51. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-e55.
52. [Erratum, Clin Infect Dis 2011; 53:319]
53. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011; 17 (Suppl 6):E1-E59.
54. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl 3):iii1-iii55.
55. Murray C, Shaw A, Lloyd M, et al. A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother 2014; 69:515-518.
56. Christ-Crain M, Stolz D, Bissinger R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93.
57. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory infections. Cochrane Database Syst Rev 2012; 9:CD007498.
58. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-474.
59. Torres A, Siliba O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313:677-686.
60. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015; 385:1511-1518.
61. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28:346-351.
62. Jiang HL, Chen HX, Liu W, et al. Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis. Respirology 2015; 20:1046-1054.
63. Gomez-Junyent J, Garcia-Vidal C, Viasus D, et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One 2014; 9:e105854.
64. Murcia J, Llorens P, Sanchez-Paya J, et al. Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population. J Infect 2010; 61:458-464.
65. Ewig S, Bauer T, Richter K, et al. Prediction of in-hospital death from community-acquired pneumonia by varing CRB-age groups. Eur Respir J 2013; 41:917-922.
66. Lee J, Kim K, Jo Y, et al. Severe thinness is associated with mortality in patients with community-acquired pneumonia: a prospective observational study. Am J Emerg Med 2015; 33:209-213.
67. Prescott HC, Sjoding MW, Iwashyna TJ. Diagnoses of early and late read-missions after hospitalization for pneumonia. A systematic review. Ann Am Thor Soc 2014; 11:1091-1100.
68. Andruska A, Micek ST, Shindo Y, et al. Pneumonia pathogen characterization is an independent determinant of hospital readmission. Chest 2015; 148:103-111.